VEGFA and VEGFB

  • Number of citations of the paper that reports this interaction (PubMedID 8702615)
  • 25
  • Data Source:
  • HPRD (in vivo)

VEGFA

VEGFB

Description vascular endothelial growth factor A vascular endothelial growth factor B
Image
GO Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
  • Adiponectin levels ( 22479202)
  • Advanced age-related macular degeneration ( 26691988)
  • Age-related macular degeneration ( 23455636 21665990)
  • Blood protein levels ( 30072576 29875488)
  • Body mass index ( 25673413)
  • Chronic kidney disease ( 20383146)
  • Coronary artery disease ( 29212778)
  • Coronary heart disease ( 22319020)
  • Creatinine levels ( 31015462 29124443 29403010)
  • Cytokine levels ( 31679650)
  • Cytokine network levels (multivariate analysis) ( 31679650)
  • Diastolic blood pressure ( 30224653)
  • Estimated glomerular filtration rate ( 31015462 29124443 30604766)
  • Fasting glucose change (short-term) ( 31263163)
  • Glomerular filtration rate ( 27588450 29403010)
  • Glomerular filtration rate (creatinine) ( 28452372 26831199)
  • Glomerular filtration rate in non diabetics (creatinine) ( 26831199)
  • HDL cholesterol ( 24097068)
  • HDL cholesterol levels ( 28334899 30698716)
  • HDL cholesterol levels in current drinkers ( 30698716)
  • HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
  • HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
  • HDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535)
  • Heel bone mineral density ( 30598549)
  • Hematocrit ( 27863252)
  • Hemoglobin concentration ( 27863252)
  • High density lipoprotein cholesterol levels ( 29403010)
  • High light scatter reticulocyte percentage of red cells ( 27863252)
  • Hyperthyroidism ( 30367059)
  • Hyperuricemia ( 29124443)
  • Hypothyroidism ( 27182965)
  • Interleukin-10 levels ( 27989323)
  • Interleukin-12p70 levels ( 27989323)
  • Interleukin-13 levels ( 27989323)
  • Interleukin-7 levels ( 27989323)
  • Medication use (calcium channel blockers) ( 31015401)
  • Medication use (HMG CoA reductase inhibitors) ( 31015401)
  • Metabolic syndrome ( 31589552)
  • Myeloid white cell count ( 27863252)
  • Plasma thyroid-stimulating hormone levels ( 28333968)
  • Prostate-specific antigen levels ( 28139693)
  • Red blood cell count ( 27863252)
  • Reticulocyte count ( 27863252)
  • Reticulocyte fraction of red cells ( 27863252)
  • Serum uric acid levels ( 30993211 29124443)
  • Sexual dimorphism in anthropometric traits ( 23754948)
  • Thyroid hormone levels ( 23408906)
  • Thyroid stimulating hormone levels ( 25743335)
  • Triglyceride levels ( 28334899 29403010 30698716)
  • Triglyceride levels in current drinkers ( 30698716)
  • Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
  • Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
  • Triglyceride levels x long total sleep time interaction (2df test) ( 31719535)
  • Triglycerides ( 24097068 25961943)
  • Type 2 diabetes ( 18372903 24509480 30054458 29358691 30297969)
  • Urate levels ( 31578528 23263486)
  • Urinary albumin-to-creatinine ratio ( 31630189)
  • Vascular endothelial growth factor levels ( 26910538 27989323 31217265)
  • Waist circumference adjusted for BMI (adjusted for smoking behaviour) ( 28443625)
  • Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction) ( 28448500)
  • Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625)
  • Waist circumference adjusted for BMI in active individuals ( 28448500)
  • Waist circumference adjusted for BMI in inactive individuals ( 28448500)
  • Waist circumference adjusted for BMI in non-smokers ( 28443625)
  • Waist circumference adjusted for body mass index ( 25673412 28448500)
  • Waist-hip ratio ( 25673412 20935629)
  • Waist-to-hip ratio adjusted for BMI ( 26426971)
  • Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625)
  • Waist-to-hip ratio adjusted for BMI (age <50) ( 26426971)
  • Waist-to-hip ratio adjusted for BMI (age >50) ( 26426971)
  • Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) ( 28448500)
  • Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625)
  • Waist-to-hip ratio adjusted for BMI in active individuals ( 28448500)
  • Waist-to-hip ratio adjusted for BMI in non-smokers ( 28443625)
  • Waist-to-hip ratio adjusted for BMI x sex interaction ( 26426971)
  • Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971)
  • Waist-to-hip ratio adjusted for body mass index ( 26785701 25673412 28448500)
  • White blood cell count ( 27863252)
  • Crohn's disease ( 28067908)
  • Triglycerides ( 30275531)
  • Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625)
  • Waist-to-hip ratio adjusted for body mass index ( 25673412)
Interacting Genes 32 interacting genes: ADAMTS1 AKT1 CCN2 CRYAB ELAVL1 EPHB2 FLT1 FN1 GPC1 HIF1A HNRNPD IGFBP7 KDR LYVE1 MDM2 NRP1 NRP2 PGF PRRG4 SEMA3F SP1 SP3 SPARC TFAP2A TNXB U2AF1 UBIAD1 VEGFB VPS35 VTN YBX1 YBX3 6 interacting genes: ADRB2 FLT1 KLHL12 NRP1 TNXB VEGFA
Entrez ID 7422 7423
HPRD ID 01889 03237
Ensembl ID ENSG00000112715 ENSG00000173511
Uniprot IDs A0A024RD33 A0A024RD37 A0A0Y0IMM4 A2A2V4 P15692 P49765 Q7LAP4
PDB IDs 1BJ1 1CZ8 1FLT 1KAT 1KMX 1MJV 1MKG 1MKK 1QTY 1TZH 1TZI 1VGH 1VPF 1VPP 2FJG 2FJH 2QR0 2VGH 2VPF 3BDY 3P9W 3QTK 3S1B 3S1K 3V2A 4DEQ 4GLN 4GLS 4KZN 4QAF 4WPB 4ZFF 5DN2 5FV1 5FV2 5HHC 5HHD 5O4E 5T89 6BFT 6D3O 2C7W 2VWE 2XAC
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?